These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 27777770)

  • 21. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
    Liew DFL; Leung JLY; Liu B; Cebon J; Frauman AG; Buchanan RRC
    Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.
    Papadopoulos KP; Lakhani N; Falchook GS; Riley G; Baeck J; Brown KS; Gordon G; Le L; Wang JS
    Cancer Immunol Immunother; 2021 Mar; 70(3):763-772. PubMed ID: 32989552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
    Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
    J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
    Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
    J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
    Tiu C; Wong A; Herschtal A; Mileshkin L
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):337-342. PubMed ID: 29498208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
    Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.
    Santini FC; Rizvi H; Plodkowski AJ; Ni A; Lacouture ME; Gambarin-Gelwan M; Wilkins O; Panora E; Halpenny DF; Long NM; Kris MG; Rudin CM; Chaft JE; Hellmann MD
    Cancer Immunol Res; 2018 Sep; 6(9):1093-1099. PubMed ID: 29991499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.
    Queirolo P; Spagnolo F
    Cancer Treat Rev; 2017 Sep; 59():71-78. PubMed ID: 28756306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases.
    Kolla BC; Patel MR
    J Immunother Cancer; 2016; 4():80. PubMed ID: 27895919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
    Shazib MA; Woo SB; Sroussi H; Carvo I; Treister N; Farag A; Schoenfeld J; Haddad R; LeBoeuf N; Villa A
    Oral Dis; 2020 Mar; 26(2):325-333. PubMed ID: 31642136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
    Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
    Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma.
    Abu-Sbeih H; Ali FS; Qiao W; Lu Y; Patel S; Diab A; Wang Y
    Cancer Immunol Immunother; 2019 Apr; 68(4):553-561. PubMed ID: 30666357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies.
    Rogado J; Romero-Laorden N; Sanchez-Torres JM; Ramos-Levi AM; Pacheco-Barcia V; Ballesteros AI; Arranz R; Lorenzo A; Gullon P; Garrido A; Serra López-Matencio JM; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondejar R; Colomer R
    Oncoimmunology; 2020; 9(1):1751548. PubMed ID: 32363123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.
    Cortellini A; Buti S; Agostinelli V; Bersanelli M
    Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM
    Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP
    J Immunother Cancer; 2017 Dec; 5(1):102. PubMed ID: 29254506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
    Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
    In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.